DeepTek.ai Receives FDA Clearance For Chest X-ray AI
DeepTek.ai, an Indian medical imaging AI company received clearance from the U.S. Food and Drug Administration (FDA) for its Chest X-ray AI solution CXR Analyser, the company informed in a statement.
This technology uses deep learning algorithms to detect abnormalities in chest X-rays to identify, categorise, and highlight suspicious areas automatically, aiding clinicians in making precise interpretations, the company said in a statement.
DeepTek's Chest X-ray AI covers the entire chest area and can analyse a broad range of lung, pleural, cardiac pathologies and foreign bodies/hardware on the chest and is compatible with various X-ray machines, including hospital-based, mobile, portable, hand-held, and ultra-portable units, the company's statement read.
The AI model can detect and locate suspicious lesions in chest X-rays, which are crucial for diagnosing conditions like lung infections, cancer, and chronic lung diseases.
Dr Amit Kharat, Co-Founder of DeepTek.ai, said "DeepTek CXR Analyser v1.0 is a game-changer, reducing radiologist workload by an impressive 30-50 per cent. With FDA clearance, we're not only accessing the vast US healthcare market but also impacting lives globally. By swiftly identifying lung abnormalities and offering precise mapping, we're unlocking a world of possibilities for improved outcomes across various medical specialities."
The company informed that, with its operations in Pune, DeepTek has approximately 200 members and has cultivated partnerships with entities like TATA Capital, NTT DATA Japan, and Shimadzu Asia Pacific.
